GNA Biosolutions nets USD 13.5 Million in a Series C Funding GNA Biosolutions has secured USD 13.5 Million completing its all the rounds of financing. GNA Biosolutions GmbH, a Germany-based molecular diagnostics company has been able to successfully secure IVD-CE marking of its first point-of-care (POC) molecul...
Find MoreNarcolepsy is characterized by symptoms such as excessive daytime sleepiness, cataplexy (sudden loss of muscle control, often triggered by strong emotions) and fragmented sleep. Narcolepsy occurs throughout the world but occurrence rates vary among populations. Occurrence of Narcolepsy is estimated to be 1 in 2,000 ...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.